Integrating AMR surveillance into wastewater monitoring systems in 2025
a position on the implementation of Article 17 of the Urban Wastewater Treatment Directive (UWWTD)
Louise Hock (Luxembourg Institute of Science and Technology)
Roosmarijn Luiken (Rijksinstituut voor Volksgezondheid en Milieu (RIVM))
Elisabete Valério (National Institute of Health Doutor Ricardo Jorge)
Marta Vargha (National Center for Public Health and Pharmacy)
Julia Vierheilig (Technische Universität Wien, Interuniversity Cooperation Centre Water & Health)
Stefan Börjesson (Norwegian Veterinary Institute)
Tarja Pitkänen (National Institute for Health and Welfare, University of Helsinki)
Heike Schmitt (Rijksinstituut voor Volksgezondheid en Milieu (RIVM), TU Delft - BT/Environmental Biotechnology)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The recast Urban Wastewater Treatment Directive (UWWTD) calls for monitoring antimicrobial resistance (AMR) in wastewater of large European agglomerations (≥ 100,000 person equivalents). Guidance on scope and methods is currently in development. Two European Joint Actions share a goal to harmonise procedures and indicators: the European Union (EU)-Wastewater Integrated Surveillance for Public Health (EU-WISH), aiming to strengthen wastewater-based surveillance (WBS) for public health and the EU-Joint Action Antimicrobial Resistance and Healthcare Associated Infections (EU-JAMRAI) 2, providing among others, approaches for environmental surveillance of AMR. An EU-WISH survey in 2024, mapping WBS AMR-related activities across Europe, revealed that of 27 countries surveyed, 11 had an operative AMR WBS system and mainly employed WBS to determine AMR trends, primarily through culture-based analyses, in-depth characterisation of specific bacteria, and quantitative PCR for specific resistance genes. Occasionally metagenomics was used. We argue that prioritising AMR WBS targets should consider the intended objectives of surveillance, which could include uncovering AMR trends and emerging AMR determinants in humans, the assessment of antimicrobial/AMR environmental release, and wastewater treatment efficiency. Targets should be assessed for their public health relevance and the usefulness of complementary information they provide, while integrating measurability, resource efficiency, and expertise from different One Health domains.
help_outline